Impact of Standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke (MonDAFIS)
Sponsor: Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Listed as NCT02204267, this NA trial focuses on Atrial Fibrillation and Stroke and remains completed. Sponsored by Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma, it has been updated 10 times since 2014, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Dec 2020 — Jan 2021 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Feb 2020 — Dec 2020 [monthly]
Active Not Recruiting NA
▶ Show 5 earlier versions
-
Sep 2019 — Feb 2020 [monthly]
Active Not Recruiting NA
-
Aug 2018 — Sep 2019 [monthly]
Active Not Recruiting NA
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting NA
-
Oct 2017 — Jun 2018 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Oct 2017 [monthly]
Recruiting NA
First recorded
Dec 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
- Charite University, Berlin, Germany
For direct contact, visit the study record on ClinicalTrials.gov .